-
- Dr. Greg Riely: My Approach to Repeat Biopsies For Advanced NSCLC Patients Who Have Insufficient Tissue for Molecular Testing
by GRACE Video on May 24, 2013 in GRACE :: Lung Cancer
Dr. Greg Riely, from Memorial Sloan-Kettering, expresses his practice pattern for patients with advanced non-small cell lung cancer who would need a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.
[powerpress]... (Read More)
- Dr. Karen Kelly: Recommending a Repeat Biopsy with Acquired Resistance to a Targeted Therapy
by GRACE Video on May 21, 2013 in GRACE :: Lung Cancer
Dr. Karen Kelly, of the University of California, Davis, reviews her thought process in recommending a repeat biopsy after progression for patients with advanced lung cancer.
[powerpress]... (Read More)
- Dr. Phil Bonomi: How Should We Manage Acquired Resistance with a Single Lesion or More Diffuse Progression?
by GRACE Video on May 20, 2013 in GRACE :: Lung Cancer
Dr. Phil Bonomi, from Rush University, offers his insights on how to approach a patient with gradual progression in a single site, especially in the brain, or more multifocal progression after a good initial response to a targeted agent.
[powerpress]... (Read More)
- Dr. David Spigel: How Do I Discuss the Side Effects of Targeted Therapies, as Compared with Chemotherapy?
by GRACE Video on May 20, 2013 in GRACE :: Lung Cancer
Dr. David Spigel, Sarah Cannon Cancer Center, discusses his perspective on side effects of targeted therapies as compared with standard chemotherapy for patients with lung cancer.
[powerpress]... (Read More)
- How to Find the Latest Info Directly from ASCO 2013
by Dr West on May 19, 2013 in GRACE :: News/Info
We're now in full-on pre-ASCO mode, with the conference just under two weeks away (May 31 to June 4th). Between now and then, I'll be working on some presentations I'll be doing while there, as well as planning a round table with GRACE faculty members Nate Pennell (fr... (Read More)
- Dr. Rosalyn Juergens: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?
by GRACE Video on May 19, 2013 in GRACE :: Lung Cancer
Dr. Rosalyn Juergens, McMaster University, discusses the question of widespread availability of new mutation tests under the Canadian health care system.
[powerpress]... (Read More)
- Dr. Sarah Goldberg on "Which molecular marker tests do you seek?"
by GRACE Video on May 18, 2013 in GRACE :: Lung Cancer
Dr. Sarah Goldberg from Yale Cancer Center describes which molecular markers she seeks for NSCLC patients.
[powerpress]... (Read More)
- New FDA Indication for First Line Tarceva in EGFR Mutation-Positive NSCLC May Be Good for Roche but BAD for Patients: Here's Why
by Dr West on May 17, 2013 in GRACE :: Lung Cancer
Earlier this week, the FDA approved the oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Tarceva (erlotinib) for the approximately 10% of advanced NSCLC patients with an activating EGFR mutation in North America and Europe (approximately 30% ... (Read More)
- Dr. Heather Wakelee on "My Approach to Maintenance Therapy for Advanced NSCLC"
by GRACE Video on May 17, 2013 in GRACE :: Lung Cancer
Dr. Heather Wakelee, from Stanford University, discusses the evidence and her personal interpretation and recommended approach to maintenance therapy for advanced non-small cell lung cancer.
[powerpress]... (Read More)
- Dr. Sumanta (Monty) Pal: What Are the Options for Second Line Treatment of Kidney Cancer?
by GRACE Video on May 16, 2013 in GRACE :: Kidney Cancer
Dr. Sumanta (Monty) Pal, medical oncologist at City of Hope Cancer Center in Duarte, CA, explains the range of options and his approach to second line treatment of kidney cancer.
[powerpress]... (Read More)
